US20210113464A1 - Disease-site-specific liposomal formulation - Google Patents
Disease-site-specific liposomal formulation Download PDFInfo
- Publication number
- US20210113464A1 US20210113464A1 US16/766,992 US201716766992A US2021113464A1 US 20210113464 A1 US20210113464 A1 US 20210113464A1 US 201716766992 A US201716766992 A US 201716766992A US 2021113464 A1 US2021113464 A1 US 2021113464A1
- Authority
- US
- United States
- Prior art keywords
- compound
- group
- disease
- administration
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 49
- 201000010099 disease Diseases 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims description 277
- 238000009472 formulation Methods 0.000 title description 234
- 239000002502 liposome Substances 0.000 claims abstract description 162
- 239000000018 receptor agonist Substances 0.000 claims abstract description 71
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 49
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims abstract description 42
- 102000009079 Epoprostenol Receptors Human genes 0.000 claims abstract 23
- 150000001875 compounds Chemical class 0.000 claims description 335
- 238000000034 method Methods 0.000 claims description 196
- 238000001990 intravenous administration Methods 0.000 claims description 85
- 239000002245 particle Substances 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 150000003904 phospholipids Chemical class 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 35
- 239000006185 dispersion Substances 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 30
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical class NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 18
- 239000007972 injectable composition Substances 0.000 claims description 17
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 15
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 15
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 claims description 14
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims description 13
- 238000011068 loading method Methods 0.000 claims description 13
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 230000002441 reversible effect Effects 0.000 claims description 12
- 229950009365 limaprost Drugs 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 10
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 230000000302 ischemic effect Effects 0.000 claims description 10
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 9
- 208000019693 Lung disease Diseases 0.000 claims description 9
- 229960002890 beraprost Drugs 0.000 claims description 9
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims description 9
- 230000036571 hydration Effects 0.000 claims description 9
- 238000006703 hydration reaction Methods 0.000 claims description 9
- 229960003841 selexipag Drugs 0.000 claims description 9
- 208000014001 urinary system disease Diseases 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 claims description 7
- 238000003113 dilution method Methods 0.000 claims description 7
- 238000000265 homogenisation Methods 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 208000023504 respiratory system disease Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- -1 {5-[2-({[(1E)-phenyl(pyridin-3-yl)methylene]amino}oxy)ethyl]-7,8-dihydronaphthalen-1-yl}oxy Chemical group 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000010643 digestive system disease Diseases 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000000155 melt Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000002249 Diabetes Complications Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 206010012655 Diabetic complications Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 229930182558 Sterol Natural products 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 206010002906 aortic stenosis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 238000004513 sizing Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 150000003432 sterols Chemical class 0.000 claims description 5
- 235000003702 sterols Nutrition 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 4
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 4
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 4
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 4
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 4
- 229960005249 misoprostol Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 150000003174 prostaglandin I2 derivatives Chemical class 0.000 claims description 4
- 210000001835 viscera Anatomy 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229960003559 enprostil Drugs 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 3
- 208000018035 Dental disease Diseases 0.000 claims description 2
- BBRBUTFBTUFFBU-LHACABTQSA-N Ornoprostil Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(=O)OC BBRBUTFBTUFFBU-LHACABTQSA-N 0.000 claims description 2
- 230000003205 diastolic effect Effects 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 229950009738 ornoprostil Drugs 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- WBBLIRPKRKYMTD-SGEDCAFJSA-N 2-[[5-[2-[(z)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid Chemical compound C=1CCC=2C(OCC(=O)O)=CC=CC=2C=1CCO\N=C(C=1C=NC=CC=1)\C1=CC=CC=C1 WBBLIRPKRKYMTD-SGEDCAFJSA-N 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 description 126
- 239000000243 solution Substances 0.000 description 91
- 230000000694 effects Effects 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 239000003814 drug Substances 0.000 description 66
- 229940079593 drug Drugs 0.000 description 58
- 238000012360 testing method Methods 0.000 description 52
- 102100026476 Prostacyclin receptor Human genes 0.000 description 49
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 44
- 239000000047 product Substances 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 42
- 230000004083 survival effect Effects 0.000 description 42
- 230000003442 weekly effect Effects 0.000 description 38
- 239000008363 phosphate buffer Substances 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 33
- 238000000108 ultra-filtration Methods 0.000 description 32
- 108010073099 Epoprostenol Receptors Proteins 0.000 description 30
- 238000009826 distribution Methods 0.000 description 30
- 239000000126 substance Substances 0.000 description 28
- 206010061216 Infarction Diseases 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 25
- 230000007574 infarction Effects 0.000 description 25
- 238000010586 diagram Methods 0.000 description 24
- 238000005259 measurement Methods 0.000 description 23
- 230000002861 ventricular Effects 0.000 description 23
- 235000002597 Solanum melongena Nutrition 0.000 description 22
- 239000002202 Polyethylene glycol Substances 0.000 description 21
- 235000012000 cholesterol Nutrition 0.000 description 21
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 21
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 21
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 21
- 229920001223 polyethylene glycol Polymers 0.000 description 21
- 238000000862 absorption spectrum Methods 0.000 description 18
- 230000000704 physical effect Effects 0.000 description 17
- 206010019280 Heart failures Diseases 0.000 description 15
- 230000002354 daily effect Effects 0.000 description 15
- 238000002592 echocardiography Methods 0.000 description 15
- 238000009210 therapy by ultrasound Methods 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 239000008186 active pharmaceutical agent Substances 0.000 description 13
- 238000002224 dissection Methods 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 13
- 230000004217 heart function Effects 0.000 description 13
- 210000005240 left ventricle Anatomy 0.000 description 13
- 239000002504 physiological saline solution Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 229940088679 drug related substance Drugs 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000002105 nanoparticle Substances 0.000 description 10
- 238000003260 vortexing Methods 0.000 description 10
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 9
- 0 C1=CC=CC=C1.[1*]OC(=O)COC.[2*]c([3*])nObc.[2HH] Chemical compound C1=CC=CC=C1.[1*]OC(=O)COC.[2*]c([3*])nObc.[2HH] 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000002077 nanosphere Substances 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 159000000000 sodium salts Chemical class 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical group CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 8
- 208000004852 Lung Injury Diseases 0.000 description 7
- 206010069363 Traumatic lung injury Diseases 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 7
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 7
- 229960003065 bosentan Drugs 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 231100000515 lung injury Toxicity 0.000 description 7
- 229920001427 mPEG Polymers 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 244000061458 Solanum melongena Species 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000012062 aqueous buffer Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- SDEURMLKLAEUAY-JFSPZUDSSA-N (2-{[(2r)-2,3-bis[(13z)-docos-13-enoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC SDEURMLKLAEUAY-JFSPZUDSSA-N 0.000 description 4
- WBBLIRPKRKYMTD-BYCLXTJYSA-N 2-[[5-[2-[(e)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid Chemical compound C=1CCC=2C(OCC(=O)O)=CC=CC=2C=1CCO\N=C(C=1C=NC=CC=1)/C1=CC=CC=C1 WBBLIRPKRKYMTD-BYCLXTJYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 238000001061 Dunnett's test Methods 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 102100037907 High mobility group protein B1 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241001041510 Oxytelinae group Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101150109738 Ptger4 gene Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000005248 left atrial appendage Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 208000024691 pancreas disease Diseases 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 229940067626 phosphatidylinositols Drugs 0.000 description 2
- 150000008106 phosphatidylserines Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- MBZYKEVPFYHDOH-UHFFFAOYSA-N (10S)-3c-Hydroxy-4.4.10r.13t.14c-pentamethyl-17t-((R)-1.5-dimethyl-hexyl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21C MBZYKEVPFYHDOH-UHFFFAOYSA-N 0.000 description 1
- NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2r)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-UHFFFAOYSA-N (3-hexadecanoyloxy-2-octadecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- YEDDVXZFXSHDIB-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluoropropan-1-ol Chemical compound OC(F)(F)C(F)(F)C(F)F YEDDVXZFXSHDIB-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 1
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MBZYKEVPFYHDOH-BQNIITSRSA-N 24,25-dihydrolanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@]21C MBZYKEVPFYHDOH-BQNIITSRSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 102000055207 HMGB1 Human genes 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 208000009433 Moyamoya Disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000947853 Vibrionales Species 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- XQEJFZYLWPSJOV-XJQYZYIXSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosa Chemical compound CC(O)=O.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 XQEJFZYLWPSJOV-XJQYZYIXSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000349 age related macular degeneration inhibitor Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 229940072271 diprivan Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- LEZNRPFLOGYEIO-QSEDPUOVSA-N ganglioside GT1b Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@]4(O[C@H]([C@H](NC(C)=O)[C@@H](O)C4)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 LEZNRPFLOGYEIO-QSEDPUOVSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 150000002298 globosides Chemical class 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 231100000806 hepatocarcinogenicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 108700014314 sandostatinLAR Proteins 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000009489 vacuum treatment Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
Definitions
- the present invention relates to a disease-site-specific liposomal formulation.
- Compound (A) (ONO-1301) is a low-molecular-weight compound having both PGI2 receptor (IP) agonism and thromboxane (TX) A2 synthase inhibitory activity.
- Compound (A) which has PGI2 agonistic activity, is known to be useful for prevention and/or treatment of thrombosis, arteriosclerosis, ischemic heart disease, gastric ulcer, hypertension, etc. (Patent Literature (PTL) 1).
- prostaglandin (PG) I2 receptor (IP) agonists can be used as endogenous repair factor production promoters for many diseases at low doses by inducing many body regeneration factors, such as a hepatocyte growth factor (HGF), a vascular endothelial cell growth factor (VEGF), a stromal cell-derived factor (SDF-1), and a high-mobility group box protein 1 (HMGB1); and these agonists are known to be useful as regenerative therapies (Patent Literature (PTL) 2).
- HGF hepatocyte growth factor
- VEGF vascular endothelial cell growth factor
- SDF-1 stromal cell-derived factor
- HMGB1 high-mobility group box protein 1
- PLA polylactic acid polymers
- PLGA lactic acid-glycolic acid copolymers
- Drugs used in microspheres include bioactive peptides, various hormones, growth factors, antibodies, peptides such as genes and various cell growth/differentiation inducing factors, proteins, nucleic acids, and the like.
- Compound (A) Patent Literature (PTL) 3
- compound (B) and compound (C) Patent Literature (PTL) 4 are known as low-molecular compounds.
- These drugs can be administered, for example, by intramuscular administration, subcutaneous injection, or patch application to various organs, of an MS formulation; in a dosage form that can continuously maintain the drug concentration in the tissue at a disease site, or in a dosage form that can maintain the blood concentration, such as intravenous infusions.
- these formulations for administration When administered at a disease site, maintain a high drug concentration in the vicinity of an administration site, and exhibit intravenous infusion-like blood kinetics; and do not have a drug delivery system (DDS) effect, which is an effect of accumulating a drug at a disease site.
- DDS is a technique for delivering a required amount of a drug to a required place at a required time.
- NS formulations are known as DDS formulations, which are intravenously administered to utilize vascular permeability enhancement action at inflammatory sites, ischemic sites, and/or cancer tissues; and utilize disease site-specific drug accumulation.
- DDS formulations which are intravenously administered to utilize vascular permeability enhancement action at inflammatory sites, ischemic sites, and/or cancer tissues; and utilize disease site-specific drug accumulation.
- a clinically applicable NS formulation comprising a PGI2 receptor agonist, such as compound (A) has been difficult due to the stability, content, yield, safety, sustained release rate, efficacy, etc., of the formulation.
- Breakdown methods are methods of pulverizing particles by spray-drying or a like method to reduce the particle size to submicron size.
- Build-up methods are known to produce, for example, polymer capsule formulations comprising a lactic acid-glycolic acid copolymer (PLGA), a lactic acid polymer (PLA), etc.; drug-encapsulating micelle formulations comprising micellar nanoparticles (polymer micelles) that have a two-layer structure comprising a block copolymer (copolymer) formed by combining polyethylene glycol (PEG) and a polyamino acid; hydrogel formulations produced by crosslinking gelatin, collagen, or a polymer mixture of hyaluronic acid, alginic acid, and the like, to form a hydrogel, and immobilizing a cell growth factor or the like in the hydrogel; and liposomal formulations having a drug encapsulated in various phospho
- an NS formulation containing a drug an NS formulation of several nanometers to 400 nm is recommended due to its enhanced permeation and retention effect (EPR effect).
- vascular endothelial cells unlike normal vascular endothelial cells, there is a wide gap of about 200 nm between vascular endothelial cells in cancer tissue or at an inflammation or ischemic site; it is known that a microparticle formulation having a size controlled to about 100 nm, or a polymer formulation, can be accumulated in tissue of vascular lesions created by cancer, infectious disease, ischemia, inflammation, arteriosclerosis, rheumatism, or the like.
- an NS formulation having a DDS effect there is known a method of forming an NS formulation having a particle size adjusted to 50 nm to 200 nm to allow a drug to reach a lesion site and release the drug at the lesion site, thus enhancing its therapeutic effect.
- NS formulations are known to pass through a cell membrane and exhibit effects in cells. It is known to produce, for example, an oral nanosphere formulation having calcitonin encapsulated in lactic acid-glycolic acid copolymer (PLGA) nanoparticles (Non-patent Literature (NPL 1)); a transpulmonary nanosphere formulation having calcitonin encapsulated in chitosan nanoparticles (NPL 2); a topical nanosphere formulation having steroid encapsulated in PLGA nanoparticles (NPL 3); and a nanosphere formulation having an anti-inflammatory agent or a mitochondrial injury inhibitor encapsulated in lactic acid-glycolic acid copolymer (PLGA) nanoparticles.
- PLGA Non-patent Literature
- Such nanosphere formulations are effective for treating ischemic reperfusion injury (Patent Literature (PTL) 5). Further, a nanosphere formulation having prostaglandin E1 or a derivative thereof encapsulated in lactic acid-glycolic acid copolymer (PLGA) nanoparticles is also known (PTL 6 and NPL 4). Further, a nanosphere formulation comprising beraprost encapsulated in lactic acid-glycolic acid copolymer (PLGA) nanoparticles is known to be effective for pulmonary hypertension (PTL 7).
- a nanoparticle formulation having a large surface area has a very short drug-release time.
- the liposomal formulation gradually releases the drug through enzymatic degradation by lipase etc. in vivo.
- a pharmaceutical composition comprising, as an active ingredient, a liposome in which an immunosuppressive agent, such as FK506, FTY720, or cyclosporin A, is encapsulated is also known to be effective for treating cardiovascular inflammatory diseases, such as myocardial infarction, myocarditis, and vasculitis syndrome (PTL 8).
- an immunosuppressive agent such as FK506, FTY720, or cyclosporin A
- Doxil produced by Janssen Pharmaceutical K.K.
- doxorubicin an anticancer antibiotic
- This pharmaceutical composition is also commercially available for other purposes, such as an antifungal agent, a Kaposi's sarcoma inhibitor, a lymphomatous meningitis inhibitor, an age-related macular degeneration inhibitor, and a postoperative pain inhibitor.
- LipoPGE 1 which is encapsulated in lipid microspheres in the form of an o/w emulsion of prostaglandin E1 comprising egg yolk lecithin, oleic acid, olive oil, and glycerin, is already commercially available (Ripple, sold by Mitsubishi Tanabe Pharma Corporation) (NPL 4).
- LipoPGE 1 which has an average particle size as large as 200 to 300 nm and has no stealth property, is trapped by the liver and macrophages, and thus has a short blood retention time.
- An object of the present invention is to provide a disease site-specific stealth liposomal formulation that is effective for treating a cardiovascular disease, such as ischemic and dilated cardiomyopathy, obstructive arteriosclerosis, vasculitis syndrome, valvular disease, aortic stenosis, chronic heart failure, or diastolic dysfunction; a respiratory disease, such as pulmonary hypertension, pulmonary fibrosis, asthma, or chronic obstructive pulmonary disease; a gastrointestinal or urinary disease, such as chronic kidney disease, chronic hepatitis, or chronic pancreatitis; and a neurodegenerative disease, such as cerebral infarction chronic stage, Alzheimer's disease, diabetic neuropathy, Parkinson's disease, or amyotrophic lateral sclerosis.
- a cardiovascular disease such as ischemic and dilated cardiomyopathy, obstructive arteriosclerosis, vasculitis syndrome, valvular disease, aortic stenosis, chronic heart failure, or di
- an object of the present invention is to provide a clinically applicable, safe and convenient, stealth liposomal formulation, which is a liposome (LP) formulation containing, for example, a PGI2 receptor agonist compound (A), and which is intermittently administered by intravenous injection, inhalation, or the like; and thereby specifically accumulated at a disease site, thus exhibiting a DDS effect.
- LP liposome
- A PGI2 receptor agonist compound
- LP stealth liposome
- a liposomal formulation that is a microparticle drug carrier coated with, for example, PEG-modified phosphoethanolamine and phospholipids can improve drug release control and stability, as well as exhibit new functions, such as accumulation at a disease site (targeting) and adhesion to tissue; thus significantly improving bioavailability (BA) and drug efficacy and thereby providing an increased effect at a lower dose than each component used alone, and reducing side effects.
- a liposomal formulation that is a microparticle drug carrier coated with, for example, PEG-modified phosphoethanolamine and phospholipids can improve drug release control and stability, as well as exhibit new functions, such as accumulation at a disease site (targeting) and adhesion to tissue; thus significantly improving bioavailability (BA) and drug efficacy and thereby providing an increased effect at a lower dose than each component used alone, and reducing side effects.
- BA bioavailability
- the present inventors conducted intensive research to solve the above problems, and found for the first time that in a liposomal formulation containing a PGI2 receptor (IP) agonist, such as compound (A), an appropriate combination of the types and composition ratio of lipids such as a phospholipid component and PEG-modified phosphoethanolamine having stealth properties; the average particle size of the liposomal formulation; the weight ratio of compound (A) or the like to the phospholipid; etc., surprisingly allows for the control of the release rate of a PGI2 receptor agonist, such as compound (A), which is a low molecular compound, and thus improves accumulation at a disease site, thereby exhibiting a DDS effect.
- IP PGI2 receptor
- the present inventors further found that a specific combination of lipids allows the liposomal formulation to retain stealth properties, so that liposomes can escape capture by macrophages or the like. Further, the inventors found that the method of the present invention can reliably produce a stealth liposomal formulation with a high yield.
- the present invention has been accomplished through further trial and error based on these findings, and includes the following inventions.
- a pharmaceutical composition for disease site-specific treatment comprising a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
- composition according to Item 1 wherein the prostaglandin I2 receptor agonist includes at least a compound represented by formula (I):
- f represents an integer of 1 to 3
- p represents an integer of 1 to 4,
- r represents an integer of 1 to 3
- R 1 represents a hydrogen atom or a C 1-4 alkyl group
- R 2 represents (i) a hydrogen atom, (ii) a C 1-8 alkyl group, (iii) a phenyl group or a C 4-7 cycloalkyl group, (iv) a 4- to 7-membered monocyclic ring containing one nitrogen atom, (v) a C 1-4 alkyl group substituted with a benzene ring or a C 4-7 cycloalkyl group, or (vi) a C 1-4 alkyl group substituted with a 4- to 7-membered monocyclic ring containing one nitrogen atom; and
- R 3 represents (i) a C 1-8 alkyl group, (ii) a phenyl group or a C 4-7 cycloalkyl group, (iii) a 4- to 7-membered monocyclic ring containing one nitrogen atom, (iv) a C 1-4 alkyl group substituted with a benzene ring or a C 4-7 cycloalkyl group, or (v) a C 1-4 alkyl group substituted with a 4- to 7-membered monocyclic ring containing one nitrogen atom;
- R 2 and R 3 are optionally substituted with one to three C 1-4 alkyl groups, C 1-4 alkoxy groups, halogen atoms, nitro groups, or trihalomethyl groups); or
- composition according to Item 1, wherein the prostaglandin I2 receptor agonist includes at least the following compound (A):
- composition according to Item 1, wherein the prostaglandin I2 receptor agonist includes at least one of the following compounds (B) to (E):
- composition according to Item 1 wherein the prostaglandin I2 receptor agonist includes at least one member selected from the group consisting of ONO-1301, beraprost, limaprost, and NS-304.
- the liposome is obtainable by a production method comprising the following steps (1) to (8):
- step (4) heating the freeze-dried product obtained in step (4) to disperse the heated product in an aqueous phosphate buffer solution
- step (6) ultrafiltrating the dispersion obtained in step (6) to remove unencapsulated material
- the liposome contains at least 0.001 mg of the prostaglandin I2 receptor agonist per 1.0 mg of the phospholipid and has an average particle size of 50 to 200 nm.
- composition for intravenous administration, intracoronary administration, inhalation, intramuscular injection, subcutaneous administration, oral administration, transmucosal administration, transdermal administration, or an internal organ; and is in the form of an injectable formulation, an oral preparation, an inhalant, a nebulizer, an ointment, a patch, or a spray.
- composition according to any one of Items 1 to 9, wherein a single intravenous dose of the composition is 0.001 to 100 mg in terms of the prostaglandin I2 receptor agonist.
- composition according to Item 11 wherein a disease to be treated with the composition is cardiovascular disease, respiratory disease, urinary disease, gastrointestinal disease, bone disease, neurodegenerative disease, vascular disease, dental disease, eye disease, skin disease, other inflammatory disease, ischemic organ disorder, diabetic complication, tissue fibrotic disease, tissue degenerative disease, or hair loss; and
- the composition comprises a liposome.
- the pharmaceutical composition according to Item 11, wherein the disease to be treated with the composition is a cardiovascular disease such as ischemic and dilated cardiomyopathy, atherosclerosis obliterans, vasculitis syndrome, valvular disease, aortic stenosis, chronic heart failure, or diastolic failure; a respiratory lung disease such as pulmonary hypertension, pulmonary fibrosis, asthma, or chronic obstructive pulmonary disease; a gastrointestinal or urinary disease such as chronic kidney disease, chronic hepatitis, or chronic pancreatitis; or a neurodegenerative disease such as chronic phase of cerebral infarction, Alzheimer's disease, diabetic neuropathy, Parkinson's disease, or amyotrophic lateral sclerosis; and
- the composition comprises a liposome.
- a pharmaceutical composition that is effective for, for example, cardiovascular diseases, respiratory diseases, gastrointestinal or urinary diseases, and inflammatory diseases such as neurodegenerative diseases, ischemic organ disorders, diabetic complications, tissue fibrotic diseases, tissue degenerative disease, or hair loss.
- the pharmaceutical composition of the present invention can have the effect of enhancing drug efficacy at a lower dose than a single use of a PGI2 receptor agonist, and also reducing side effects.
- the present invention can provide a stealth liposomal formulation that allows for accumulation of a PGI2 receptor agonist in a high concentration at a disease site, and exhibit effects in a sustained manner; and provide a method for producing the stealth liposomal formulation.
- the liposomal formulation of the present invention containing compound (A) or the like is effective for circulatory diseases, respiratory diseases, urinary diseases, gastrointestinal diseases, and neurodegenerative diseases, when intermittently administered by intravenous administration, intramuscular administration, subcutaneous administration, or inhalation administration.
- the liposomal formulation administered intravenously or by inhalation is accumulated at a disease site and topically exhibits an endogenous repair factor production-promoting action, thus being useful as a regenerative drug.
- Intravenous administration of the liposomal formulation is useful for heart diseases, such as myocardial infarction, angina, dilated cardiomyopathy, aortic stenosis, valvular disease, chronic heart failure, and diastolic dysfunction, due to its vasodilator action, angiogenesis action, stem cell differentiation-inducing action, antifibrotic action, antiapoptotic action, reverse remodeling action, etc.
- heart diseases such as myocardial infarction, angina, dilated cardiomyopathy, aortic stenosis, valvular disease, chronic heart failure, and diastolic dysfunction
- pulmonary diseases or the like such as acute pneumonia, chronic pneumonia, pulmonary hypertension, pulmonary fibrosis, interstitial pneumonia, COPD, and ARDS
- inhalation administration in addition to intravenous administration, is useful.
- neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, and spinal cord injury
- FIG. 1 is diagrams showing the average particle size distribution of Formulations 1 to 4.
- FIG. 2 is diagrams showing the average particle size distribution of Formulations 5 to 8.
- FIG. 3 is a diagram showing the average particle size distribution of Formulation 9.
- FIG. 4 is a diagram showing the average particle size distribution of Formulation 10.
- FIG. 5 is diagrams showing the average particle size distribution of Formulations 11 to 14.
- FIG. 6 is diagrams showing the average particle size distribution of Formulations 15 to 18.
- FIG. 7 is a diagram showing the average particle size distribution of Formulation 19.
- FIG. 8 is a diagram showing the average particle size distribution of Formulation 20.
- FIG. 9 is a graph showing the results of quantification of compound (A).
- FIG. 10 is a diagram showing the average particle size distribution of Formulation 21.
- FIG. 11 is transmission electron microscope images of Formulation 21.
- FIG. 12 is charts of HPLC measurement of Samples 1 to 5.
- FIG. 13 is a diagram showing the average particle size distribution of Formulation 22.
- FIG. 14 is transmission electron microscope images of Formulation 22.
- FIG. 15 is an absorption spectrum of a solution of compound (B).
- FIG. 16 is a diagram showing the average particle size distribution of Formulation 23.
- FIG. 17 is transmission electron microscope images of Formulation 23.
- FIG. 18 is an absorption spectrum of compound (C).
- FIG. 19 is diagrams showing the average particle size distribution of Formulations 24 and 25.
- FIG. 20 shows the results of HPLC analysis.
- FIG. 21 shows the particle size distribution of liposomes having compound (B) encapsulated therein (Formulation 26).
- FIG. 22 shows UV absorption spectra of compound (B), and liposomes having compound (B) encapsulated therein.
- FIG. 23 shows the particle size distribution of liposomes having compound (D) encapsulated therein (Formulation 27).
- FIG. 24 is UV absorption spectra of compound (D), and liposomes having compound (D) encapsulated therein (Formulation 27).
- FIG. 25 is a diagram showing the average particle size distribution of liposomes having compound (E) encapsulated therein (Formulation 28).
- FIG. 26 is absorption spectra of compound (E) and liposomes having compound (E) encapsulated therein (Formulation 28).
- FIG. 27 shows 42-day survival curves of a group receiving ONO-1301 by repeated oral administration, and a group receiving Formulation 21 (ONO-1301LipoNS formulation) by intermittent intravenous administration.
- FIG. 28 is a graph showing the survival rates of all groups.
- FIG. 29 is a graph showing a comparison with intermittent intravenous administration of Formulation 25 (ONO-1301Lipo).
- FIG. 30 is a graph showing a comparison with intermittent intratracheal administration of Formulation 25 (ONO-1301Lipo).
- FIG. 31 is a drawing showing a method for evaluating a left ventricle wall thickness and a left ventricle wall area.
- FIG. 32 is photographs showing an infarct area evaluation method.
- the liposomes used in the pharmaceutical composition of the present invention are not limited, as long as they are closed vesicles surrounded by a lipid bilayer.
- the liposomes may be large unilamellar vesicle (LUV) liposomes, or small unilamellar vesicle (SUV) liposomes; and may be multilamellar vesicle (MLV) liposomes.
- LUV large unilamellar vesicle
- SUV small unilamellar vesicle
- MLV multilamellar vesicle
- the liposomes can be produced by known production methods.
- the Bangham method is commonly used as a liposome production method.
- methods comprising the Bangham method and some additional operations, which are called the simple hydration method, ultrasonic treatment method, and extrusion method.
- liposome production methods further include the direct dispersion method, organic solvent (e.g., ethanol) injection method, reverse phase evaporation method, calcium fusion method, surfactant removal method, static hydration method, hexane-span 80 dialysis method, organic solvent globule evaporation method, mechanochemical method, ultrasonic method, lipid-compound film method, and the like; and improved methods of these methods.
- the method for adjusting the particle size includes the extrusion method, extrusion process, French press method, and the like.
- the extruder method or the French press method includes a method comprising passing particles several times through a nanopore membrane filter having an appropriate pore size, which is set in an extruder or a French press to adjust the liposome size.
- Examples of the method for encapsulating the compound include the pH gradient (remote loading) method, counter ion concentration gradient (gelation) method, freeze-thaw method, supercritical carbon dioxide method, film loading method, and the like.
- the methods that are superior in encapsulating a water-soluble drug include the reverse phase evaporation method and the freeze-thaw method.
- the methods that are superior in encapsulating fat-soluble drugs include the Bangham method, the mechanochemical method, the supercritical carbon dioxide method, and the film loading method.
- the methods that are superior in encapsulating dissociative drugs include the pH gradient (remote loading) method, the counterionization concentration gradient method, and the like.
- the Bangham method includes, for example, a method comprising forming a lipid film; and then applying a mechanical vibration by vortexing, ultrasonic waves, or the like in an aqueous buffer to form liposomes (a hydration dispersion method).
- the reverse phase evaporation method includes, for example, a method comprising dissolving a lipid in an organic solvent that is immiscible with water; then adding an aqueous buffer and performing ultrasonic treatment to form a reverse micelle (a W/O emulsion), thereafter removing the organic solvent by vacuum treatment or the like and achieving a gel state; and then forming liposomes.
- the ethanol injection method or the ethanol dilution method includes, for example, a method comprising dissolving a lipid in ethanol, and injecting a lipid solution into an aqueous buffer to form liposomes.
- the homogenization method or the mechanochemical method includes, for example, a method of forming liposomes by using a high-pressure emulsifier.
- the direct dispersion method includes a method comprising directly dispersing a lipid or a mixture of a lipid and a compound in an aqueous buffer, without preparing a lipid film, to form liposomes.
- the extruder method or the French press method includes, for example, a method comprising passing the liposomes through a nanopore membrane set in an extruder or a French press to thereby adjust the liposome size.
- the remote loading method is an encapsulation method utilizing the difference in pH solubility of the compound. More specifically, after liposomes having as an inner aqueous phase a pH solution in which the compound is water-soluble are formed, the outer aqueous phase is replaced with a pH solution in which the compound is fat-soluble by ultrafiltration, dialysis, or the like; and adding a compound solution to the liposome dispersion to thereby encapsulate the compound in the aqueous phase of the liposomes.
- the dehydration-rehydration method is an encapsulation method in which liposomes are dehydrated by freeze-drying or the like; and then rehydrated with an aqueous buffer containing a compound to be encapsulated, thereby encapsulating the compound.
- the freeze-thawing method includes, for example, a method comprising mixing a liposome dispersion and a compound solution to be encapsulated, and repeating freeze-thaw cycles to thereby encapsulate a compound at a high concentration.
- the method for producing liposomes is not limited to the production methods described above.
- the method further includes improved methods of each of these methods, and the like.
- lipids that form liposomes are not particularly limited.
- examples of lipids include soy lecithin, hydrogenated soy lecithin, egg yolk lecithin, phosphatidylcholines, phosphatidylserines, phosphatidylethanolamines, phosphatidylinositols, phosphasphingomyelins, phosphatidic acids, long-chain alkyl phosphates, gangliosides, glycolipids, phosphatidylglycerols, sterols, and the like.
- Lipids can be used singly, or in a combination of two or more.
- Examples of phosphatidylcholines include dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, and the like.
- Examples of phosphatidylserines include dipalmitoyl phosphatidylserine, sodium dipalmitoylphosphatidylserine, bovine brain-derived sodium phosphatidylserine, and the like.
- Examples of phosphatidylethanolamines include dimyristoyl phosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, and the like.
- Examples of the phosphatidylinositols include wheat-derived phosphatidylinositol sodium, and the like.
- Examples of phosphasphingomyelins include bovine-derived sphingomyelin, and the like.
- Examples of phosphatidic acids and long-chain alkyl phosphates include dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, distearoyl phosphatidic acid, dicetyl phosphoric acid, and the like.
- Examples of gangliosides include ganglioside GM1, ganglioside GD1a, ganglioside GT1b, and the like.
- glycolipids examples include galactosylceramide, glucosylceramide, lactosylceramide, phosphatide, globoside, and the like.
- phosphatidyl glycerol examples include dimyristoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl glycerol, distearoyl phosphatidyl glycerol, and the like.
- sterols include cholesterol, dihydrocholesterol, lanosterol, dihydrolanosterol, sitosterol, campesterol, stigmasterol, brassicasterol, ergosterol, and the like.
- a phospholipid and cholesterol are preferably used in combination.
- the phospholipid is preferably a phosphatidylcholine.
- the molar ratio of the phospholipid to cholesterol is preferably in the range of 1:0.1 to 1:1.5, and more preferably 1:0.5 to 1:1.25.
- Examples of phospholipids that can be used in the present invention include the following commercially available products (sold by Nippon Fine Chemical Co., Ltd.).
- the phospholipid is preferably DOPC or DEPC, although it may vary depending on the substance to be encapsulated therein.
- liposomes comprising typical phospholipid and cholesterol.
- stealth liposomes whose surface is modified with polyethylene glycol (PEG) or the like to increase the blood retention.
- PEG polyethylene glycol
- the liposome membrane surface is preferably modified with a polyethylene glycol (PEG) derivative.
- the liposomes modified with a PEG derivative can be produced by using a covalent conjugate of PEG having a molecular weight of 500 to 20000 and a phospholipid.
- the covalent conjugate of PEG and phospholipid is preferably a PEG-modified phosphoethanolamine, which is a conjugate of PEG having a molecular weight of 200 to 5000 and distearoylphosphatidylethanolamine.
- PEG-modified phosphoethanolamines include commercially available products, such as DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), and the like (all produced by Nippon Fine Chemical Co., Ltd.), which comprise mPEG 350, mPEG 550, mPEG 750, mPEG 1000, mPEG 2000, mPEG 3000, or mPEG 5000 as a PEG-modifying group.
- DMPE 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine
- DPPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
- DSPE
- a preferable combination is, for example, a combination of mPEG2000-DSPE: N-(carbonyl-methoxypolyethyleneglycol 5000)-1,2 distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt CAS No. 147867-65-0 (produced by Nippon Fine Chemical Co., Ltd.) and DEPC: 1,2-dierucoyl-sn-glycerol-3-phosphorylcholine CAS No. 51779-95-4 (produced by Nippon Fine Chemical Co., Ltd.).
- the contents of the PEG-modified phosphoethanolamine and phospholipid are not particularly limited.
- the content of the PEG-modified phosphoethanolamine is preferably 0.01% to 10%, and more preferably 0.01% to 3%, relative to the phospholipid as 1.
- the liposome surface is modified with PEG and a targeting molecule, such as an antibody or a peptide, to increase blood retention and further enhance the transfer to a target site.
- a targeting molecule such as an antibody or a peptide
- the present invention provides a stealth liposome characterized in that the liposome contains a PGI2 receptor agonist and a phospholipid, and further comprises PEG-modified phosphoethanolamine.
- the liposome is preferably formed into a liposomal formulation by combining a PGI2 receptor agonist and a phospholipid, and further EG-modified phosphoethanolamine, according to the purpose; and mixing these components at an appropriate ratio.
- the stealth liposome comprises a prostaglandin I2 receptor agonist, a phospholipid, a PEG-modified phosphoethanolamine, and a water-miscible solvent; and can be produced, for example, by a production method comprising the following steps:
- a prostaglandin I2 receptor agonist a phospholipid, and a PEG-modified phosphoethanolamine in a water-miscible solvent in amounts such that at least 5 mg of the phospholipid and at least 0.05 mg of the PEG-modified phosphoethanolamine are present per mg of the prostaglandin I2 receptor agonist, to prepare a mixture;
- the liposomes produced by this method are a stealth liposomal formulation characterized by containing a PGI2 receptor agonist, and having an average particle size of 50 to 200 nm.
- the mixture of the PGI2 receptor agonist, the phospholipid, PEG-modified phosphoethanolamine, and solvent may or may not contain a sterol, such as cholesterol.
- Conventional liposomes preferably comprise a combination of a phospholipid and cholesterol as constituent lipids.
- the present invention uses no cholesterol as a constituent lipid, and thereby makes it possible to produce liposomes in which a PGI2 receptor agonist is stably encapsulated at a high concentration.
- the size (particle size) of the liposomes is not particularly limited.
- the liposomes preferably have an average particle size of about 10 to 1000 nm, more preferably about 20 to 500 nm, and even more preferably about 50 to 200 nm.
- the “particle size” referred to herein means the diameter of a particle determined by the dynamic light scattering method.
- a preferable polydispersity index (PDI) is 0.3 or less.
- the method for adjusting the particle size is not particularly limited.
- the present invention provides a prophylactic and/or therapeutic agent for a cardiovascular disease, a respiratory disease, a urinary disease, a vascular disease, a gastrointestinal disease, a neurodegenerative disease, etc., which comprises, as an active ingredient, liposomes having a PGI2 receptor agonist encapsulated therein.
- the PGI2 receptor agonist used in the pharmaceutical composition of the present invention is not particularly limited; a known PGI2 receptor agonist can be preferably used.
- Examples of known PGI2 receptor agonists include, for example, pharmaceutical compositions, PGI2 derivatives, and PGE derivatives, which are compounds represented by the following formula (I):
- f represents an integer of 1 to 3
- p represents an integer of 1 to 4,
- r represents an integer of 1 to 3
- R 1 represents a hydrogen atom or a C 1-4 alkyl group
- R 2 represents (i) a hydrogen atom, (ii) a C 1-8 alkyl group, (iii) a phenyl group or a C 4-7 cycloalkyl group, (iv) a 4- to 7-membered monocyclic ring containing one nitrogen atom, (v) a C 1-4 alkyl group substituted with a benzene ring or a C 4-7 cycloalkyl group, (vi) a C 1-4 alkyl group substituted with a 4- to 7-membered monocyclic ring containing one nitrogen atom; and
- R 3 represents (i) a C 1-8 alkyl group, (ii) a phenyl group or a C 4-7 cycloalkyl group, (iii) a 4- to 7-membered monocyclic ring containing one nitrogen atom, (iv) a C 1-4 alkyl group substituted with a benzene ring or a C 4-7 cycloalkyl group, (v) a C 1-4 alkyl group substituted with a 4- to 7-membered monocyclic ring containing one nitrogen atom;
- R 2 and R 3 are optionally substituted with one to three C 1-4 alkyl groups, C 1-4 alkoxy groups, halogen atoms, nitro groups, or trihalomethyl groups); and salts thereof.
- the PGI2 receptor agonist is one of the following compounds:
- (B) carbacyclic PGI2 derivatives such as sodium ( ⁇ )-(1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octene-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butanoate (CAS: 88475-69-8; beraprost)(compound (B));
- PGE derivatives such as (2E)-7 ⁇ -(1R,2R,3R)-3-hydroxy-2[-(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl ⁇ -hept-2-enoic acid (CAS: 74397-12-9; limaprost), omoprostil; 175,20-dimethyl-6-oxo-PGE 1 methyl ester, emprostil, and misoprostol (compound (D)); and
- the subject to which the pharmaceutical composition of the present invention is administered is preferably a mammal having an inflammatory disease, ischemic organ disorder, diabetic complication, tissue fibrotic disease, tissue degenerative disease, or the like.
- mammals include humans, monkeys, cows, sheep, goats, horses, pigs, rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Humans that have developed an inflammatory disease, or humans suspected to have an inflammatory disease, are particularly preferable.
- the method for administering the pharmaceutical composition of the present invention is not particularly limited, as long as the active ingredient can reach a disease site.
- Examples include injectable formulations, patches, inhalants, nebulizers, sprays, gels, creams, sprays, ointments, nasal drops, eye drops, and the like, which are for intravenous administration, intracoronary administration, drip/infusion, intracoronary administration, inhalation, intramuscular administration, subcutaneous administration, oral administration, suppositories, intraperitoneal administration, transmucosal administration, transdermal administration, or internal organs.
- intracoronary administration is preferable.
- peripheral intravenous administration is preferable.
- the injectable formulation may be either an aqueous injectable formulation or an oily injectable formulation.
- the aqueous injectable formulation can be prepared by a known method. For example, after liposomes having a drug encapsulated therein are mixed into a solution prepared by appropriately adding pharmaceutically acceptable additives to an aqueous solvent (e.g., water for injectable formulation or purified water), the resulting mixture is filtered through a filter or the like and sterilized, and the filtrate is filled into an aseptic container.
- an aqueous solvent e.g., water for injectable formulation or purified water
- Examples of pharmaceutically acceptable additives include isotonic agents such as sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, glucose, and propylene glycol; buffers such as phosphoric acid buffer, acetic acid buffer, boric acid buffer, carbonic acid buffer, citric acid buffer, Tris buffer, glutamic acid buffer, and epsilon-aminocaproic acid buffer; preservatives such as methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, and borax; thickeners such as hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, and polyethylene glycol; stabilizers such as sodium bisulfite, sodium thiosulfate, sodium
- the injectable formulation may further comprise an appropriate solubilizing agent.
- solubilizing agent include alcohols such as ethanol; polyalcohols such as propylene glycol and polyethylene glycol; nonionic surfactants such as polysorbate 80, polyoxyethylene (50) hydrogenated castor oil, lysolecithin, and pluronic polyol; and the like.
- the injectable preparation may comprise a protein such as bovine serum albumin or keyhole limpet hemocyanin; a polysaccharide such as aminodextran; and the like.
- an oily injectable formulation for example, sesame oil or soybean oil can be used as an oily solvent; and benzyl benzoate, benzyl alcohol, or the like can be added as a solubilizing agent.
- the prepared injectable formulation is usually placed in, for example, an appropriate ampoule or vial.
- Liquid formulations such as injectable formulations can also be preserved after removing water by cryopreservation, lyophilization, or the like. Lyophilized formulations are dissolved again at the time of use by adding distilled water for injectable formulations or the like; and then used.
- the amount of the drug or the like contained in the pharmaceutical composition of the present invention varies depending on the dosage form, administration interval, or administration route.
- the amount can be appropriately selected from the range of 0.001 ng/mL to 100 mg/mL.
- the administration period and administration method are appropriately determined according to the disease and the treatment method therefor, in consideration of safety, convenience, low invasiveness, patient's burden, compliance, and the like. Any administration interval may be used as long as the effect can be expected and the administration interval is convenient.
- the administration interval is preferably about twice a day, every day, once every two days, once every three days, once a week, once every two weeks, once every three weeks, or once every four weeks; and is more preferably in the range of once a day to once a week.
- a single dose in terms of ONO-1301 is preferably 500 mg or less, and more preferably 100 mg or less.
- the lower limit is not particularly limited, and can be any dose that provides the desired effect.
- the pharmaceutical composition of the present invention which comprises, as an active ingredient, liposomes having a PGI2 receptor agonist encapsulated therein, is useful in that the liposomal formulation can exhibit effects on many diseases even at a low dose due to its accumulation at a disease site by the DDS effect. That is, vascular permeability at a lesion site, and nano-sized liposomes can be expected to specifically accumulate in the lesion site (EPR effect).
- the liposomal formulation is highly useful in that since the drug moves into cells due to the endocytosis effect, an increase in drug efficacy and a reduction in side effects can be expected.
- the pharmaceutical composition of the present invention is useful in that an active ingredient can be delivered to a target lesion site by administration through a peripheral vein or the like, without the necessity of using a central venous catheter or the like. Another advantage is that the pharmaceutical composition is difficult to be delivered to sites other than the target site even when administered through a peripheral vein.
- the pharmaceutical composition of the present invention is highly useful in that the composition can provide an enhanced tissue repair effect at a low dose; and can reduce side effects by reducing the dose, suppressing delivery to sites other than the target site, and eliminating the necessity of using a central venous catheter or the like.
- the solvent used When a liposomal formulation is to be produced by the direct dispersion improvement method, and when a premix of lipids is produced, the solvent used must meet the following conditions: it is a solvent in which lipids and the substance to be encapsulated are soluble; it can be instantly frozen; and it can be removed by freeze-drying. Any solvent that satisfies the above conditions can be used.
- the solvent is preferably t-butanol, cyclohexane+ethanol, hexafluoropropanol, 1-propanol, isopropyl alcohol, 2-butoxyethanol, and the like.
- t-Butanol is more preferable.
- a sugar such as maltose, sucrose, or trehalose
- PGI2 receptor agonists such as compound (A) have, for example, an in vivo regeneration factor production-promoting action, stem cell differentiation-inducing action, anti-apoptotic action, reverse remodeling action, anti-fibrotic action, and angiogenesis-promoting action. Therefore, stealth liposomal formulations containing such a PGI2 receptor agonist are useful as therapeutic and/or prophylactic agents for the following various diseases:
- vascular diseases e.g., atherosclerosis obliterans (ASO), Berger disease, Raynaud's disease, arteriosclerosis, vasculitis syndrome, etc.
- cardiovascular diseases e.g., myocardial infarction, myocarditis, angina, supraventricular tachyarrhythmia, congestive heart failure, coronary artery disease, idiopathic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, atrial fibrillation, chronic heart failure, diastolic dysfunction, systolic dysfunction, valvular disease, aortic stenosis, etc.
- neurodegenerative diseases e.g., ischemic encephalopathy, cerebrovascular disease, stroke, Parkinson's disease, Alzheimer's disease, diabetic neuropathy, spinal canal stenosis, dementia, moyamoya disease, spinal cord injury, muscle atrophy lateral sclerosis (ALS) etc.
- respiratory diseases e.g., vascular diseases
- the liposomal formulation of the present invention has shown promise as a prophylactic and/or therapeutic agent for heart diseases, lung diseases, kidney diseases, bone diseases, neurodegenerative diseases, liver diseases, pancreatic diseases, autoimmune diseases, allergic syndromes, and vascular diseases.
- VEGF vascular endothelial cell growth factor
- HGF hepatocyte growth factor
- a/bFGF various fibroblast growth factors
- TGF- ⁇ transforming growth factor- ⁇
- PDGF platelet-derived growth factor
- Angiopoietin a hypoxia-inducible factor
- IGF insulin-like growth factor
- BMP bone morphogenetic protein
- CTGF connective tissue growth factor
- EGF epidermal growth factor
- SDF-1 stromal cell-derived factor
- HMGB1 high-mobility group box 1
- Examples of other drugs that produce endogenous repair factors described above include other PGI2 receptor agonists, EP2 and EP4 receptor agonists of PGE2 receptors, and mixed receptor agonists thereof, and the like.
- the drugs mentioned above may be used in place of compound (A).
- Examples of the drug that can be used in place of compound (A) include PGI and PGE derivatives, IP, EP2 and EP4 receptor agonists, and the like.
- Specific examples include compound (B), aeroprost, ornoprostil, compound (C), compound (D) (limaprost), compound (E), enprostil, misoprostol, ONO-4232, ONO-8055, and the like.
- two or more drugs selected from compound (A) and drugs described above are combined according to the purpose, and formed into liposomes.
- the drugs may be commercially available, or can be easily produced in accordance with a known method.
- the dosage form of the liposome of the present invention includes injectable formulations, ointments, patches, oral preparations, sprays, and the like, which are for intravenous administration, coronary artery administration, inhalation, intramuscular administration, subcutaneous administration, oral administration, transmucosal administration, and transdermal administration, or internal organs.
- injectable formulations, ointments, patches, oral preparations, sprays, and the like which are for intravenous administration, coronary artery administration, inhalation, intramuscular administration, subcutaneous administration, oral administration, transmucosal administration, and transdermal administration, or internal organs.
- other examples include implants, transmucosal agents for administration through the rectum, uterus, oral cavity, or the like, nasal drops, and intravenous drip injections; or a method for continuous administration into coronary arteries.
- the liposomal formulation of the present invention is less toxic and fully safe for use as a medicament. Further, the PGI2 receptor agonist has been confirmed not to have carcinogenesis initiation and promotion effects in a long-term carcinogenicity test, a medium-term hepatocarcinogenicity test, etc., using mice and rats.
- HSPC hydrogenated soybean phospholipid, hydrogenated lecithin
- product name COATSOME NC-21 (NOF corporation)
- CAS 921228-87-5, 92128-87-5
- MPEG2000-DSPE N-(carbonyl-methoxypolyethyleneglycol-5000)-1,2 distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt, CAS: 147867-65-0 (Nippon Fine Chemical Co., Ltd.)
- DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine, CAS: 4235-95-4 (Nippon Fine Chemical Co., Ltd.)
- PBS( ⁇ ) Dulbecco's phosphate buffered saline (without Ca and Mg), filtered and sterilized, tested for mycoplasma and endotoxin (product code: 14249-95) (Nacalai Tesque Inc.)
- PGI2 receptor agonists to be encapsulated in liposome are commercially available from the companies listed below, and can be purchased generally.
- HSPC 107.4 mg
- DSPE DSPE
- cholesterol 35.3 mg
- a 0.1N sodium hydroxide solution (>pH: 12.0) was added so that the lipid concentration was 10 mg/mL.
- the mixture was redispersed by vortexing, and subjected to ultrasonic treatment for 30 minutes in total using a VS-100III produced by AS ONE Corporation by repeating a cycle of 28 kHz output for 60 seconds, 45 kHz output for 60 seconds, and 100 kHz output for 3 seconds. After the ultrasonic treatment, the particle size was confirmed.
- the three concentration conditions were a 1/10 mixing ratio: 3.29 mg of the compound and 32.9 mg of the lipids; a 2/10 mixing ratio: 6.58 mg of the compound and 32.9 mg of the lipids; and a 4/10 mixing ratio: 13.16 mg of the compound and 32.9 mg of the lipids.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 1 is diagrams showing the average particle size distribution of these formulations.
- HSPC (102.0 mg), DSPE (8.5 mg), and cholesterol (33.5 mg) were weighed and placed in an eggplant flask, and a chloroform/methanol solution (1/1, v/v) was added and dissolved so that the lipid concentration was 20 mg/mL.
- Treatment was performed for 60 minutes in total using a VS-100III, produced by AS ONE Corporation, by repeating a cycle of 28 kHz output for 60 seconds, 45 kHz output for 60 seconds, and 100 kHz output for 3 seconds.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 2 is diagrams showing the average particle size distribution of these formulations.
- HSPC 255.0 mg
- DSPE 21.3 mg
- cholesterol 83.0 mg
- a chloroform/methanol solution (1/1, v/v) was added and dissolved so that the lipid concentration was 20 mg/mL.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 50-mL cell): Model 8050 5122 produced by Merck & Co., Inc., and BioMax PBMK 04310 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 3 is a diagram showing the average particle size distribution of this formulation.
- Lipids (HSPC: 21.2 mg, DSPE: 1.8 mg, and cholesterol: 7.0 mg) and compound (A) (6.0 mg) were weighed and placed in an eggplant flask. At this time, the amounts were adjusted so that compound A) was present in an amount of 2 mg per 10 mg of the lipids.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 4 is a diagram showing the average particle size distribution of this formulation.
- HSPC (107.5 mg), MPEG2000-DSPE (35.0 mg), and cholesterol (35.5 mg) were weighed and placed in an eggplant flask, and a chloroform/methanol solution (1:1, v/v) was added and dissolved so that the lipid concentration was 30 mg/mL.
- the liposome external solution was 10 mM phosphate buffer (pH: 8.0) (liposome solution).
- the ultrafiltration was performed using a stirred cell (8000 series, a 50-mL cell): Model 8050 5122 produced by Merck & Co., Inc., and BioMax PBMK 04310 produced by Merck & Co., Inc. After the preparation of empty liposomes, lipid quantification was performed.
- the compound (A) solution was added to the liposome solution (three concentration conditions), and the mixture was stirred at 60° C. for 1 hour.
- the three concentration conditions were a 1/10 mixing ratio: 4.0 mg of compound (A) and 40.0 mg of the lipids; a 2/10 mixing ratio: 8.0 mg of compound (A) and 40.0 mg of the lipids; and a 4/10 mixing ratio: 16.0 mg of compound (A) and 40.0 mg of the lipids.
- Free compound (A) was removed by stirred ultrafiltration (cutoff molecular weight: 300,000 Da). Ultrafiltration was performed by using a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc. The external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 5 is diagrams showing the average particle size distribution of these formulations.
- HSPC 7.0 mg
- MPEG2000-DSPE 28.3 mg
- cholesterol 29.0 mg
- the three concentration conditions were a 1/10 mixing ratio: 1.0 mg of compound (A) and 10.0 mg of the lipids; a 2/10 mixing ratio: 2.0 mg of compound (A) and 10.0 mg of the lipids; and a 4/10 mixing ratio: 4.0 mg of compound (A) and 10.0 mg of the lipids.
- Ultrasonic treatment was performed for 60 minutes in total using a VS-100III produced by AS ONE Corporation by repeating a cycle of 28 kHz output for 60 seconds, 45 kHz output for 60 seconds, and 100 kHz output for 3 seconds.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 6 is diagrams showing the average particle size distribution of these formulations.
- HSPC 215.0 mg
- MPEG2000-DSPE 70.0 mg
- cholesterol 71.0 mg
- a chloroform/methanol solution (1:1, v/v) was added and dissolved so that the lipid concentration was 30 mg/mL.
- Ultrasonic treatment was performed for 1 minute and for 30 minutes in total using a VS-1001 produced by AS ONE Corporation by repeating a cycle of 28 kHz output for 60 seconds, 45 kHz output for 60 seconds, and 100 kHz output for 3 seconds to separate the lipids from the wall of the eggplant flask, and the resulting product was stirred at 60° C. for 30 minutes.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 50-mL cell): Model 8050 5122 produced by Merck & Co., Inc., and BioMax PBMK 04310 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 7 shows is diagrams showing the average particle size distribution of this formulation.
- HSPC (18.0 mg), MPEG2000-DSPE (6.0 mg), cholesterol (6.0 mg), and compound (A) (6.0 mg) were weighed and placed in an eggplant flask. At this time, the amounts were adjusted so that compound (A) was present in an amount of 2 mg per 10 mg of the lipids. Then, a chloroform/methanol solution (1/1, v/v) was added and dissolved so that the total weight of the lipids and compound (A) was 30 mg/mL.
- Free compound (A) was removed by ultrafiltration (cutoff molecular weight: 300,000 Da) using a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc.
- the external solution was a 10 mM phosphate buffer (pH: 7.4).
- FIG. 8 is a diagram showing the average particle size distribution of this formulation.
- a calibration curve was prepared by measuring the absorbance at wavelength of 265 nm with respect to 6 different compound (A) concentrations of 0.0 mg/mL to 0.50 mg/mL.
- a PEG-treated compound (A)-encapsulated liposome was prepared in large quantities by the Bangham method, and the properties were tested.
- a stirred cell (8000 series, a 400-mL cell): Model 8400 5124 produced by Merck & Co., Inc., and BioMax PBMK 07610 produced by Merck & Co., Inc. were used. Since the solution amount was 930 mL in total, three cells were used for ultrafiltration (cutoff molecular weight: 300,000 Da) to replace the outer aqueous phase with 10 mM phosphate buffer (pH 7.4), and unencapsulated compound (A) was removed.
- FIG. 10 is a diagram showing the average particle size distribution of this formulation.
- FIG. 11 is transmission electron microscope images of Formulation 21.
- Photographing device Hitachi H-7600 at 100 kV
- FIG. 11 shows electron micrographs.
- Sample 1 Compound (A) was dissolved in a 1M sodium hydroxide solution so that compound A was 1 mg/mL. The resulting product was allowed to stand at 40° C. overnight (oxide production sample).
- Sample 2 Compound (A) was added to a 0.1N sodium hydroxide solution-10 mM phosphate buffer (pH: 8.0) (buffer for encapsulation) so that compound (A) was 0.5 mg/mL (control sample)
- Sample 3 Sample 2 was subjected to two-fold dilution with physiological saline to prepare a solution of 0.25 mg/mL. The solution was allowed to stand at 37° C. overnight (compound control sample).
- Sample 4 PEG-treated empty liposomes were diluted 10-fold with physiological saline. The resulting product was allowed to stand at 37° C. overnight, followed by ultrafiltration (lipid control sample).
- Sample 5 The PEG-treated compound (A)-encapsulated liposome was diluted 10-fold with physiological saline. The resulting product was allowed to stand at 37° C. overnight, followed by ultrafiltration (liposome sample).
- FIG. 12 charts of HPLC measurement of Samples 1 to 5.
- a stirred cell (8000 series, a 10-mL cell): Model 8010 5121 produced by Merck & Co., Inc., and BioMax PBMK 02510 produced by Merck & Co., Inc. were used. The amount was 6 mL at the time of start and 4 mL at the time of collection, and 1.5-fold concentration was performed. Since the drug encapsulation amount was low, ultrafiltration (cutoff molecular weight: 300,000 Da) was performed to replace the outer aqueous phase with 10 mM phosphate buffer (pH 7.4), and unencapsulated compound (B) was removed.
- FIG. 13 is a diagram showing the average particle size distribution of this formulation.
- FIG. 14 is transmission electron microscope images of Formulation 22.
- FIG. 15 is a graph showing changes in the UV absorption spectrum.
- HSPC (60.0 mg), cholesterol (12.0 mg), and MPEG2000-DSPE (12.0 mg) were weighed and placed in an eggplant flask, a chloroform/methanol (1/1, v/v) solution was added so that the lipid concentration was 30 mg/mL, and the mixture was dissolved by stirring at 37° C.
- FIG. 16 is a diagram showing the average particle size distribution.
- FIG. 17 is transmission electron microscope images of Formulation 23.
- FIG. 18 is a graph showing changes in the UV absorption spectrum of compound (C).
- composition 1 Composition 2 Lipid or API (Formulation 24) (Formulation 25) DEPC 1.88 g 1.80 g MPEG2000-DSPE 0.12 g 0.20 g Compound (A) 100 mg 100 mg
- Ultrafiltration (ultrafiltration membrane: PBMK04310, Merck Millipore, cutoff molecular weight: 300,000 Da) was performed using PBS( ⁇ ) (10-fold dilution of SIGMA D1408) to remove unencapsulated compounds.
- Ultrafiltration was performed using a stirred cell, 8000 series: Model 8050, product No. 5122, produced by Merck & Co., Inc.
- 8000 series Model 8050, product No. 5122, produced by Merck & Co., Inc.
- BioMax PBMK 04310,300 kDa produced by Merck & Co., Inc.
- the liposome solution was subjected to ultrafiltration (cutoff molecular weight: 300,000 Da) with PBS( ⁇ ): Dulbecco's phosphate buffered saline (without Ca and Mg), and the resulting product was used as a sample after ultrafiltration. Additionally, the presence or absence of oxides of ONO-1301 was confirmed by HPLC.
- Extruder treatment was performed while heating at 37° C.
- a LIPEX extruder 100 mL was used. After treatment was performed once with a polycarbonate filter with a pore size of 400 nm, treatment was performed three times with a polycarbonate filter with a pore size of 200 nm (treatment pressure: about 5 MPa).
- the extruder used was a Lipex Thermobarrel Extruder (100 mL) produced by Northern Lipids, and the membranes used were Nuclepore membranes produced by GE Healthcare (400 nm: Product No. 111107; 200 nm: Product No. 111106).
- the ultrafiltration was performed using a stirred cell, 8000 series: Model 8050, product No. 5122, produced by Merck & Co., Inc.
- a stirred cell 8000 series: Model 8050, product No. 5122, produced by Merck & Co., Inc.
- BioMax PBMK 04310, 300 kDa, produced by Merck & Co., Inc. was used.
- the liposome solution was introduced into the stirred cell, the apparatus was set, and feeding of the solution was performed by nitrogen gas pressurization (0.4 MPa) until 140 mL of waste liquid was discharged.
- the compound (B)-encapsulated liposome had the physical properties shown in Table 16 and FIG. 21 . As shown in FIG. 22 , UV absorption derived from compound (B) was observed in the UV absorption spectrum of the compound (B)-encapsulated liposome. Table 16 below shows the properties (the particle size, PdI value, and zeta potential) of the obtained liposome. FIG. 21 shows the liposome particle size distribution of Formulation 26.
- FIG. 22 shows UV absorption spectra of compound (B) (Beriplast) and liposomes containing the compound (B).
- the amount of encapsulated compound (D) was 0.249 mg/mL according to UV quantification.
- the obtained liposome had the properties shown in Table 17 below; i.e., the particle size, PdI value, and zeta potential.
- FIG. 23 shows the liposome particle size distribution of Formulation 27.
- FIG. 24 is UV absorption spectra of compound (D) (Limaprost) and liposomes containing Limaprost.
- Formulation 27 Lipid Encapsulated Average particle Zeta potential (mg/mL) amount (mg/mL) size (nm) PdI (mV) 6.0 0.249 110 0.200 ⁇ 19
- a compound (E)-encapsulated liposome had the physical properties shown in Table 18 and FIG. 25 .
- the amount of encapsulated compound (E) was 0.305 mg/mL according to UV quantification.
- the table below shows the particle size, PdI value, and zeta potential.
- the absorption spectra of FIG. 26 shows quantitativity at UV absorption of 300 nm.
- Formulation 28 Lipid Encapsulated Average particle Zeta potential (mg/mL) amount (mg/mL) size (nm) PdI (mV) 5.9 0.305 131 0.171 ⁇ 36
- the produced Formulation 21 (ONO-1301Lipo formulation) as a test substance was intermittently administered intravenously once weekly to a rat monocrotaline (MCT)-induced severe heart failure (pulmonary hypertension) model from day 7 of the MCT administration, and the survival rate was compared with a group in which compound (A) (ONO-1301) was repeatedly orally administered; a group in which compound (A) was intermittently administered intravenously once weekly; and, as a positive control, a group in which an ET-1 antagonist (bosentan) was orally administered.
- physiological saline (vehicle) was administered once weekly by intravenous administration.
- MCT Monocrotaline
- SLBG1999V Sigma-Aldrich Corporation
- Group 1 Physiological saline was intravenously administered 7, 14, 21, 28, and 35 days after the MCT administration at weekly intervals (5 times in total).
- Group 2 Compound (A) was orally administered at 3 mg/kg twice daily from 7 days to 41 days after the MCT administration with administration intervals of 8 hours or more.
- Group 3 Bosentan was orally administered at 50 mg/kg twice daily from 7 days to 41 days after the MCT administration with administration intervals of 8 hours or more.
- Group 4 Formulation 21 (ONO-1301Lipo) was intravenously administered at 1 mg/kg 7, 14, 21, 28, and 35 days after the MCT administration at weekly intervals (5 times in total).
- Group 5 Compound (A) was intravenously administered at 1 mg/kg 7, 14, 21, 28, and 35 days after the MCT administration at weekly intervals (5 times in total).
- FIG. 27 shows changes in the survival rates of Group 1, Group 2, and Group 4 until 42 days after the preparation of the severe heart failure model.
- Table 20 shows the survival rates of all of the groups after 42 days.
- Bosentan which is an ET-1 antagonist, used in the positive control, has been clinically used as a therapeutic agent for pulmonary hypertension, and the efficacy thereof has been confirmed in the same rat MCT-induced heart failure model (Circ. J. 2013; 77: 2127-2133).
- these results are based on repeated oral administration immediately after the MCT administration. This time, a significant life-prolonging effect could not be observed in the administration started 7 days after the MCT administration (Group 3).
- the amount was 210 mg/kg/animal (3 mg/kg ⁇ twice/day ⁇ 35 days) in Group 2, 3500 mg/kg/animal (50 mg/kg ⁇ twice/day ⁇ 35 days) in Group 3, and 5 mg/kg/animal (1 mg/kg/week ⁇ 5 times) in Group 4 and Group 5.
- Group 4 showed an effect similar to that of Group 2 at a 5/210 (1/42) dose amount of Group 2.
- a novel ONO-1301 liposomal formulation (Formulation 21; ONO-1301Lipo) was produced to analyze the development of a therapeutic method for developing a more versatile, disease site-specific (DDS) therapeutic agent for a severe heart failure, by intermittent intravenous administration.
- the DDS effect was confirmed by comparing the survival rates in the MCT-induced severe heart failure model by the intermittent intravenous administration of Formulation 21.
- Bosentan which is an ET-1 antagonist, and used as the positive control substance, has been clinically used as a therapeutic agent for pulmonary hypertension; and the efficacy thereof has been confirmed in the MCT-induced heart failure model.
- these results are based on repeated oral administration immediately after the MCT administration. This time, a significant life-prolonging effect could not be observed in the administration treatment 7 days after the MCT administration.
- the final survival rate of the group in which compound (A) was repeatedly administered at 3 mg/kg twice daily (Group 2) was 50%, which showed a significant life-prolonging effect compared with the control group (Group 1).
- mice C57BL/6NCr female mice (7 weeks old) were anesthetized with sodium pentobarbital, and then intratracheally (intrapulmonary) administered with 20 ⁇ L of a bleomycin hydrochloride aqueous solution (BLM) twice (40 ⁇ L in total per animal).
- BBM bleomycin hydrochloride aqueous solution
- vehicle physiological saline
- test substance was administered to compare the survival rates.
- compound (A) (ONO-1301) was repeatedly orally administration twice daily, compound (A) (ONO-1301) was intravenously administered once weekly, and compound (A) (ONO-1301) was intratracheally administered once weekly.
- Formulation 25 (ONO-1301Lipo) was intravenously administered once weekly, and Formulation 25 (ONO-1301Lipo) was intratracheally administered once weekly to analyze the DDS effect of Formulation 25 (ONO-1301Lipo) by comparing the survival rates.
- the vehicle and compound (A) were repeatedly orally administered twice daily for 23 days (the administration interval between morning and afternoon was 8 hours or more).
- Dose amount 5 mL/kg ⁇ twice/day
- Administration method Gavage oral administration using a disposable polypropylene syringe and a mouse stomach tube
- the administration was performed 6 days after the preparation of the lung injury model; after that, tail vein intravenous administration was performed once weekly (4 times in total, i.e., 6, 13, 20, and 27 or 28 days after the preparation of the model).
- Administration method Intravenous administration using a glass syringe and a disposable injection needle 30G
- the administration was performed 6 days after the preparation of the lung injury model; after that, intratracheal administration was performed once weekly (4 times in total, i.e., 6, 13, 20, and 27 or 28 days after the preparation of the model).
- intratracheal administration was performed once weekly (4 times in total, i.e., 6, 13, 20, and 27 or 28 days after the preparation of the model).
- physiological saline was administered in a similar manner.
- Dose amount 0.5 mL/kg
- FIGS. 28 to 30 Show the Results of the Survival Rates.
- FIG. 29 Comparison with Intermittent Intravenous Administration of Formulation 25 (ONO-1301Lipo)
- the total dose amount of compound (A) (ONO-1301) (3 mg/kg ⁇ twice ⁇ 22 days) was 132 mg/kg.
- the total dose amount of intravenous administration of compound (A) (ONO-1301) at 3 mg/kg once weekly (Group 3) was 12 mg/kg
- the total dose amount of intravenous administration of Formulation 25 at 1 mg/kg once weekly (Group 4) was 4 mg/kg.
- the total dose amount of intravenous administration of Formulations 25 at 3 mg/kg once weekly (Group 5) was 12 mg/kg.
- the survival rate in the vehicle group (Group 1) was 30%.
- the survival rates of Group 4 dose amount: 1/33 of the total dose amount of Group 2)
- Group 5 dose amount: 1/11 of the total dose amount of Group 2
- the group in which the compound (A) (ONO-1301) drug substance was intravenously administered at 3 mg/kg once weekly (Group 5) showed an even lower survival rate (40%) at a dose amount 1/11 that of Group 2.
- FIG. 30 Comparison with Intermittent Intratracheal Administration of Formulation 25 (ONO-1301Lipo)
- the total dose amount of compound (A) (ONO-1301) (3 mg/kg ⁇ twice ⁇ 22 days) was 132 mg/kg.
- the total dose amount of intratracheal administration of compound (A) (ONO-1301) at 1 mg/kg once weekly (Group 6) was 4 mg/kg, and the total dose amount of intratracheal administration of Formulation 25 at 0.3 mg/kg once weekly (Group 7) was 1.2 mg/kg.
- the total dose amount of intratracheal administration of Formulation 25 at 1 mg/kg once weekly (Group 8) was 4 mg/kg.
- the survival rate in the vehicle administration group was 30%.
- Group 7 dose amount: 1/110 of the total dose amount of Group 2
- Group 8 dose amount: 1/33 of the total dose of Group 2 showed survival rates of 50% and 40%, respectively.
- intratracheal administration of Formulation 25 at 0.3 mg/kg once weekly showed the same survival rate (50%) as those of the intravenous administration of Formulation 25 at 1 mg/kg or 3 mg/kg once weekly. This suggested that intratracheal administration exhibits a DDS effect greater than that of the intravenous administration.
- the intravenous administration of Formulation 25 once weekly showed a prolonging effect on the survival rate, compared with intravenous administration of the compound (A) (ONO-1301) drug substance once weekly (Group 3). Further, Groups 4 and 5 showed a slightly lower survival rate than that of the group of repeated oral administration of the compound (A) (ONO-1301) drug substance twice daily (Group 2), although the total dose amounts of Groups 4 and 5 were as low as 1/11 to 1/33 that of Group 2.
- intratracheal administration of Formulation 25 at 0.3 mg/kg once weekly showed the same survival rate (50%) as those of intravenous administration of Formulation 25 at 1 mg/kg or 3 mg/kg once weekly, suggesting that the intratracheal administration achieves a greater DDS effect, i.e., about 10 times that of the intravenous administration.
- Formulation 25 was used by suspending and diluting with physiological saline.
- Compound (A) (ONO-1301) as a control was used by dissolving in an equivalent amount of aqueous NaOH, and diluting with physiological saline.
- administration was performed as a suspension in a 0.5% CMC-Na aqueous solution.
- J2N-k spontaneous dilated cardiomyopathy
- Liquid dose 5 mL/kg
- Test start date Animals arrived at the age of 18 weeks were subjected to a 2-week quarantine/acclimation period, and then to the test at the time of grouping (test start date) at the age of 20 weeks. Thereafter, tests were conducted 4 and 8 weeks after the test start date, and dissection was performed 8 weeks after the test start date.
- the final echocardiography was performed 8 weeks after the start of administration. Thereafter, dissection was performed.
- Dissection was performed as follows. After all of the blood was collected from the abdominal aorta, and the hamsters were euthanized under isoflurane anesthesia, the heart and lungs were removed and weighed. After the weights thereof were measured, the removed parts, including the left and right ventricles, were divided into three parts; i.e., apical, middle, and basal parts, at intervals of about 2 mm along the short axis.
- the short-axis sections including the right and left ventricles of the middle part were immersed in 4% paraformaldehyde (for general pathological examination), and stored.
- the heart including the left and right ventricles, was divided into three parts; i.e., apical, middle, and basal parts, at intervals of about 2 mm along the short axis. Among them, one section of the middle part was photographed, and the wall thickness at the anterior, lateral, posterior, and septum parts, and the left ventricular area were measured using image-editing software.
- the wall thickness of the left ventricle image-editing software was used, the number of pixels in the scale area of 1 mm 2 on the photograph was obtained, and the outer diameter and inner diameter of the entire left ventricle wall were traced to obtain each number of pixels to thus calculate the left ventricular area by ((the number of pixels of the outer diameter ⁇ the number of pixels of the inner diameter)/1 mm 2 ). Thereafter, the wall thickness of each portion was measured.
- FIG. 31 shows the measurement method.
- the section was divided into three parts; i.e., apical, middle, and basal areas, at intervals of about 2 mm. Thereafter, using one section on the middle side, the wall thickness at the anterior, lateral, posterior, and septum parts, and the left ventricular area were measured.
- image-editing software was used, the number of pixels in the scale area of 1 mm 2 on the photograph was obtained, and the outer diameter and inner diameter of the entire left ventricle wall were traced to obtain each number of pixels to thus calculate the left ventricular wall area by ((the number of pixels of the outer diameter ⁇ the number of pixels of the inner diameter)/1 mm 2 ). Thereafter, the wall thickness of each portion was measured.
- Table 23 shows the measurement results of EF % values and % FS values determined by echocardiography.
- Echocardiography was performed at the time of grouping, and at week 4 and week 8 after the start of administration. The measurement was performed 3 times for each individual, and the average value of the measured data was referred to as the measurement results.
- the EF % values at the time of grouping, and at week 4 and week 8 were 42.5 ⁇ 3.2%, 33.6 ⁇ 12.3%, and 31.5 ⁇ 3.5%, respectively.
- the EF % value at week 8 showed a significant decrease (p ⁇ 0.05) compared with the EF % value at the time of grouping.
- the % FS values at the time of grouping and at week 4 and week 8 were 17.8 ⁇ 1.4%,13.3 ⁇ 6.1%, and 12.6 ⁇ 1.6%, respectively. Similar to the EF % value, the EF % value at week 8 showed a significant decrease (p ⁇ 0.01) compared with the % FS value at the time of grouping.
- the EF % values of the group of repeat oral administration of compound (A) (ONO-1301) at 3.0 mg/kg ⁇ twice/day (Group 4) at the time of grouping and at week 4 and week 8 were 43.0 ⁇ 7.8%, 40.4 ⁇ 14.9%, and 40.3 ⁇ 9.2%, respectively. Compared with the value at the time of grouping, the values at week 4 and week 8 showed no significant decrease in cardiac function. The EF % value at week 8 was higher than that of the control group, showing a significant difference (p ⁇ 0.05).
- the % FS values at the time of grouping and at week 4 and week 8 were 18.2 ⁇ 3.9%, 17.2 ⁇ 7.2%, and 17.1 ⁇ 4.5%, respectively, which were similar to the EF % values.
- the EF % values of the group of intravenous administration of compound (A) (ONO-1301) at 3.0 mg/kg (Group 3) at the time of grouping and at week 4 and week 8 were 38.8 ⁇ 4.3%, 35.7 ⁇ 7.4%, and 30.8 ⁇ 2.9%, respectively.
- the decrease at week 4 was slower than that of the control group; however, the decrease at week 8 was similar to that of the control group.
- the EF % value at week 8 showed a significant decrease (p ⁇ 0.01) from the value at the time of grouping.
- the % FS values at the time of grouping and at week 4 and week 8 were 16.0 ⁇ 2.1%, 16.1 ⁇ 3.1%, and 12.3 ⁇ 1.3%, respectively. These results were similar to the EF % values, showing no efficacy.
- the EF % value of the group of intravenous administration of Formulation 25 (ONO-1301Lipo) at 3.0 mg/kg (Group 2) at the time of grouping and at week 4 and week 8 were 40.5 ⁇ 5.1%, 44.5 ⁇ 9.9%, and 39.6 ⁇ 4.1%, respectively. Although the difference was not significant, a slight increase was observed at week 4. At week 8, the decrease was suppressed in a manner similar to that of the group of oral administration of compound (A) (ONO-1301) at 3.0 mg/kg, and the value was significantly higher (p ⁇ 0.05) compared with that of the control group.
- the % FS values at the time of grouping and at week 4 and week 8 were 16.9 ⁇ 2.6%,18.5 ⁇ 4.9%, and 16.5 ⁇ 2.1%, respectively; thus, the change was similar to that of the EF % values.
- the value at week 8 showed a significant effect (p ⁇ 0.01) compared with that of the control group (Group 1), and this effect was similar to that of the group of repeat oral administration of compound (A) (ONO-1301) (Group 4).
- Table 24 shows the wall thickness measurement results.
- the wall thicknesses of the apical, lateral, posterior, and septum of the middle section in the control group were 0.8 ⁇ 0.1 mm, 1.1 ⁇ 0.2 mm, 1.1 ⁇ 0.2 mm, and 1.0 ⁇ 0.2 mm, respectively.
- the wall thicknesses of the apical, lateral, posterior, and septum of the middle section were 1.4 ⁇ 0.5 mm, 1.5 ⁇ 0.2 mm, 1.2 ⁇ 0.4 mm, and 1.5 ⁇ 0.3 mm, respectively.
- the thicknesses of the apical, lateral, and septum were significantly higher (p ⁇ 0.05) than those of the control group.
- Group 3 compound (A) 4 128.7 ⁇ 10.4 144.4 ⁇ 13.3 1.1 ⁇ 0.6 1.2 ⁇ 0.3 1.2 ⁇ 0.2 1.0 + 0.3 (ONO-1301): 3.0 mg/kg, intravenous administration Group 2; Formulation 25: 5 119.6 ⁇ 10.5 138.8 ⁇ 12.4 1.7 ⁇ 0.4** 1.5 ⁇ 0.1* 1.5 ⁇ 0.6 ⁇ 1.2 ⁇ 0.3 3.0 mg/kg, intravenous administration Data shown: the mean ⁇ standard deviation ⁇ 0.05 ⁇ p ⁇ 0.1, *p ⁇ 0.05, **p ⁇ 0.01 (significantly different from the control value by Student's t-test)
- Table 25 shows the left ventricular area measurement results.
- the measurement results of the left ventricular wall area of the control group (Group 1), the group of oral administration of compound (A) (ONO-1301) at 3.0 mg/kg (Group 4), the group of intravenous administration of compound (A) (ONO-1301) at 3.0 mg/kg (Group 3), and the group of intravenous administration of Formulation 25 (ONO-1301Lipo) at 3.0 mg/kg (Group 2) were 23.4 ⁇ 5.4 mm 2 , 26.4 ⁇ 4.3 mm 2 , 23.9 ⁇ 4.5 mm 2 , and 29.5 ⁇ 6.4 mm 2 , respectively.
- the cardiac function improvement effect of Formulation 25 was analyzed using spontaneous dilated cardiomyopathy (J2N-k) hamsters.
- the test was initiated after the onset of the pathological condition, and at the age of 20 weeks when the cardiac function considerably decreased.
- the test substance was administered until week 28, and the change in the cardiac function was analyzed.
- the control group (Group 1) and the group of intravenous administration of compound (A) (ONO-1301) at 3.0 mg/kg (Group 3) showed low values, which suggested the progress of thinning.
- the group of repeat oral administration of compound (A) (ONO-1301) at 3.0 mg/kg (Group 4) and the group of Formulation 25 (ONO-1301Lipo) at 3.0 mg/kg (Group 2) showed higher values, suggesting the suppression of the progress of thinning, compared with the control group (Group 1) and the group of intravenous administration of compound (A) (ONO-1301) at 3.0 mg/kg (Group 3). This is assumed to reflect the results of EF % and % FS values determined by echocardiography.
- the total dose amount of the repeat oral administration of compound (A) (ONO-1301) at 3 mg/kg ⁇ twice ⁇ 56 days was 336 mg/kg, while the total dose amount of the intravenous administration of Formulations 25 (ONO-1301Lipo) at 3 mg/kg ⁇ 4 times was 12 mg/kg; both of these showed a similar efficacy.
- the intermittent intravenous administration of compound (A) (ONO-1301) at 3 mg/kg once every 2 weeks showed no effect. Accordingly, the intermittent intravenous administration of Formulation 25 (ONO-1301Lipo) once every 2 weeks showed the effect at a dose of 1/28 of that of the repeat oral administration of compound (A) (ONO-1301). This confirmed the DDS effect of intravenous administration of Formulation 25 (ONO-1301Lipo).
- Tables 26 and 27 show the body weight change at the time of grouping and at the time of dissection, and the weights of heart and lung at the time of dissection. No change was observed in any of these.
- Body weight (g) Body Tissue weight per 100 g weight at Real tissue weight (g) of the body weight (g) Drugs N dissection Heart Lung Heart Lung Control 4 129.4 ⁇ 6.7 0.4674 ⁇ 0.0666 0.5640 ⁇ 0.0949 0.3602 ⁇ 0.0340 0.4346 ⁇ 0.0548 Compound (A) 5 128.6 ⁇ 3.0 0.4379 ⁇ 0.0136 0.5202 ⁇ 0.0336 0.3404 ⁇ 0.0032 0.4043 ⁇ 0.0203 (ONO-1301): 3.0 mg/kg, p.o.
- a tracheal cannula (a cut-down catheter with an outside diameter of 2.0 mm, produced by JMS Co., Ltd.) was inserted and indwelled, and a respirator (for small animals; Shinano Seisakusho) was connected to maintain breathing at a stroke volume of 1 mL/100 g/stroke ( ⁇ 1 mL) and a stroke rate of 70 times/min ( ⁇ 10 times).
- the animals were fixed in a recumbent position from a dorsal fixed position so that the left chest faced upward, and the epidermis and muscle layer between the third to fourth or fourth to fifth ribs were incised with a surgical knife.
- the intercostal space was widened with a rib spreader, and a state in which the anterior descending branch (hereinafter referred to as “LAD”) from the left atrial appendage was directly visible at the front was secured.
- LAD anterior descending branch
- the translucent thin pericardium was removed with tweezers to expose the myocardium.
- the LAD located at the margin of the left atrial appendage was pierced and secured with a nylon thread with a 6-0 or 7-0 needle at a depth of 2 to 3 mm using a microneedle holder, and the LAD was completely ligated.
- the muscle layer and epidermis were sutured and closed with a 4-0 or 5-0 nylon thread. After the chest was closed, 50 mg of cefamedin was subcutaneously administered to the treatment site, and the treatment was terminated.
- Group 1 Normal — 3
- Group 2 Control Intravenous 5 (Physiological saline) administration
- Group 3 Formulation 25 Intravenous 5 (ONO-1301Lipo): 0.3 mg/kg administration
- Group 4 Formulation 25 Intravenous 5 (ONO-1301Lipo): 1.0 mg/kg administration
- Group 5 Formulation 25 Intravenous 5 (ONO-1301Lipo): 3.0 mg/kg administration
- Group 6 Compound (A) Intravenous 5 (ONO-1301): 3.0 mg/kg administration 1) Liquid dose: 5 mL/kg 2) Single intravenous administration to the tail 24 hours after infarction
- Echocardiography was performed to confirm the cardiac function improving effect of the test substances using the left ventricular ejection fraction (hereinafter referred to as “EF %”) as an index.
- EF % left ventricular ejection fraction
- test was performed 23 hours after the preparation of the model (test for grouping), the animals whose EF % value decreased by 25% or more of that of normal animals were selected, grouping was performed, and a solution for administration of the test substances was administered by tail vein intravenous administration 24 hours after the preparation of the model. Thereafter, echocardiography was performed 7 and 14 days after the test substance administration.
- Dissection was performed after the completion of the echocardiography at day 14 after the administration of the test substance.
- all of the blood was collected from the abdominal aorta, and the rats were euthanized under isoflurane anesthesia; thereafter, the heart was removed and weighed. After measuring the heart weight, the infarct area, including the left and right ventricles, was divided into three parts along the short axis.
- Tables 29 and 30 show the echocardiography results.
- the EF % values of all of the groups before the test substance administration showed a significant decrease (p ⁇ 0.01) compared with the EF % value of the normal animals; no significant difference was observed among the groups.
- the change in the EF % value of each group at day 7 and day 14 after the administration were as follows.
- the EF % value 2 weeks later showed a significant decrease (p ⁇ 0.05) compared with that before the administration.
- the EF % value at day 14 showed a significant increase (p ⁇ 0.05) compared with that of the control group.
- the increase in the EF % value showed a peak on day 7 after the administration compared with the EF % value before the administration, indicating an improvement in the cardiac function.
- the EF % values at day 7 and day 14 after the test substance administration showed a significant suppression of a decrease (p ⁇ 0.05 and p ⁇ 0.01, respectively) compared with those of the control group.
- the normal % FS value is clinically said to be 28% or more. Although the difference was slight, the % FS values of all of the groups were lower than this value.
- the % FS values of all of the groups before the test substance administration showed a significant decrease (p ⁇ 0.01) compared with the EF % value of the normal animals; no significant difference was observed among the groups.
- the change in the % FS value of each group at day 7 and day 14 after the administration were as follows.
- the % FS value 2 weeks later showed a significant decrease (p ⁇ 0.05) compared with that before the administration.
- the increase in the % FS value showed a peak on day 7 after the administration compared with the % FS value before the administration.
- the % FS values at day 7 and day 14 after the test substance administration both showed a significant increase (p ⁇ 0.05) compared with those of the control group.
- the measurement results showed correlation between the EF % and % FS values, which are used as indices of the evaluation of the cardiac function, in each group; and the single intravenous administration of Formulation 25 (ONO-1301LipoNS) at 1.0 mg/kg or 3.0 mg/kg showed a cardiac function improving effect.
- the apical portion was removed, and the middle area was sectioned into two parts at an interval of about 2 mm. Thereafter, the infarct area of the two sections on the apical and basal sides was measured. The infarct area was evaluated based on the ratio of the infarct area to the entire left ventricular area, and the ratio of the length of the normal area or the infarct area to the left ventricular outer diameter.
- FIG. 32 shows an infarct area evaluation method.
- the apical portion was removed, and the middle area was sectioned into two parts at an interval of about 2 mm. Thereafter, the infarct area of the two sections on the apical and basal sides was measured. The infarct area was evaluated based on the ratio of the infarct area to the entire left ventricular area, and the ratios of the length of the normal area or the infarct area to the left ventricular outer diameter.
- the single intravenous administration of Formulation 25 suppressed the onset of the pathological condition in the rat heart ischemia model in a dose-correlated manner. Further, the administration of Formulation 25 at 3 mg/kg showed an improving effect over the Pre. Although the single intravenous administration of the compound (A) (ONO-1301) drug substance at 3 mg/kg showed a suppression effect similar to that of Formulation 25 at 1 mg/kg, no effect was observed in terms of reducing the infarct area.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2017/042350 WO2019102606A1 (ja) | 2017-11-27 | 2017-11-27 | 疾患部位特異的リポソーム製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/042350 A-371-Of-International WO2019102606A1 (ja) | 2017-11-27 | 2017-11-27 | 疾患部位特異的リポソーム製剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/491,953 Continuation US20240082154A1 (en) | 2017-11-27 | 2023-10-23 | Disease-site-specific liposomal formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210113464A1 true US20210113464A1 (en) | 2021-04-22 |
Family
ID=66631009
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/766,992 Abandoned US20210113464A1 (en) | 2017-11-27 | 2017-11-27 | Disease-site-specific liposomal formulation |
US18/491,953 Pending US20240082154A1 (en) | 2017-11-27 | 2023-10-23 | Disease-site-specific liposomal formulation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/491,953 Pending US20240082154A1 (en) | 2017-11-27 | 2023-10-23 | Disease-site-specific liposomal formulation |
Country Status (3)
Country | Link |
---|---|
US (2) | US20210113464A1 (de) |
EP (1) | EP3718537A4 (de) |
WO (1) | WO2019102606A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
WO2024133620A1 (en) | 2022-12-22 | 2024-06-27 | Actelion Pharmaceuticals Ltd | In vitro dissolution test |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501233A (ja) * | 2012-11-30 | 2016-01-18 | インスメッド, インコーポレイテッド | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2100918C (en) | 1992-07-21 | 1997-01-21 | Nobuyuki Hamanaka | Oxime derivative |
EP1563846B1 (de) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogene reparaturfaktoren herstellende promoter |
ES2459743T3 (es) | 2006-10-19 | 2014-05-12 | Ono Pharmaceutical Co., Ltd. | Preparación de liberación sostenida para terapia de regeneración tisular |
WO2010058669A1 (ja) | 2008-11-18 | 2010-05-27 | 株式会社Lttバイオファーマ | 新規プロスタグランジンe1誘導体及びそれを封入するナノ粒子 |
JP5780775B2 (ja) | 2011-02-18 | 2015-09-16 | 株式会社Lttバイオファーマ | プロスタグランジンi2誘導体を含有するナノ粒子 |
WO2013176223A1 (ja) | 2012-05-23 | 2013-11-28 | 国立大学法人大阪大学 | 炎症性疾患治療用医薬組成物 |
ES2733998T3 (es) * | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
US20140271820A1 (en) * | 2013-03-13 | 2014-09-18 | Mallinckrodt Llc | Liposome oxaliplatin compositions for cancer therapy |
WO2015056504A1 (ja) * | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
JPWO2016006577A1 (ja) | 2014-07-07 | 2017-04-27 | 株式会社 先端医療開発 | 医薬組成物 |
-
2017
- 2017-11-27 EP EP17932885.1A patent/EP3718537A4/de active Pending
- 2017-11-27 US US16/766,992 patent/US20210113464A1/en not_active Abandoned
- 2017-11-27 WO PCT/JP2017/042350 patent/WO2019102606A1/ja unknown
-
2023
- 2023-10-23 US US18/491,953 patent/US20240082154A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501233A (ja) * | 2012-11-30 | 2016-01-18 | インスメッド, インコーポレイテッド | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 |
Non-Patent Citations (1)
Title |
---|
Niina et al. (Pancreatology 14 (2014) 201-210) (Year: 2014) * |
Also Published As
Publication number | Publication date |
---|---|
EP3718537A1 (de) | 2020-10-07 |
US20240082154A1 (en) | 2024-03-14 |
EP3718537A4 (de) | 2021-11-10 |
WO2019102606A1 (ja) | 2019-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240082154A1 (en) | Disease-site-specific liposomal formulation | |
Elmowafy et al. | Silymarin loaded liposomes for hepatic targeting: in vitro evaluation and HepG2 drug uptake | |
RU2632433C2 (ru) | Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его | |
KR100889139B1 (ko) | 이리노테칸 제제 | |
TWI355946B (en) | Proliposomal and liposomal compositions of poorly | |
CN108348538B (zh) | 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒 | |
KR101132626B1 (ko) | 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법 | |
TW202011941A (zh) | 用於治療肺部疾病的可吸入的緩釋組成物 | |
WO2023030524A1 (zh) | 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法 | |
CN108289832A (zh) | 用于以输注或注射形式进行静脉给药的左西孟旦以及输注浓缩液的改善配方 | |
US20070286898A1 (en) | Intracellular Drug Delivery Improving Liposome | |
JP4874097B2 (ja) | 水難溶性カンプトテシン含有リポソーム製剤 | |
US20150157610A1 (en) | Pharmaceutical composition for treating inflammatory disease | |
Xia et al. | Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption | |
KR101007925B1 (ko) | 경구용 지질 나노입자 및 그의 제조방법 | |
JP7186385B2 (ja) | 疾患部位特異的リポソーム製剤 | |
WO2011037252A1 (ja) | スピカマイシン誘導体を含有するリポソーム製剤 | |
KR20210102936A (ko) | 안정적인 마취제 제제 및 관련 복용량 형태 | |
KR101612194B1 (ko) | 알부민에 결합된 약물을 포함하는 나노입자가 봉입된 리포좀을 포함하는 약물 전달용 조성물 | |
EP3395370B1 (de) | Liposom und liposomzusammensetzung | |
JPWO2009125858A1 (ja) | 2−インドリノン誘導体を含有する脂質分散体製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARDIO INCORPORATED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAWA, YOSHIKI;MIYAGAWA, SHIGERU;SAKAI, YOSHIKI;AND OTHERS;SIGNING DATES FROM 20200217 TO 20200220;REEL/FRAME:052772/0264 Owner name: OSAKA UNIVERSITY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAWA, YOSHIKI;MIYAGAWA, SHIGERU;SAKAI, YOSHIKI;AND OTHERS;SIGNING DATES FROM 20200217 TO 20200220;REEL/FRAME:052772/0264 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: OSAKA UNIVERSITY, JAPAN Free format text: CHANGE OF ASSIGNEE ADDRESS;ASSIGNORS:SAWA, YOSHIKI;MIYAGAWEA, SHIGERU;SAKAI, YOSHIKI;AND OTHERS;SIGNING DATES FROM 20200217 TO 20200220;REEL/FRAME:055578/0840 Owner name: CARDIO INCORPORATED, JAPAN Free format text: CHANGE OF ASSIGNEE ADDRESS;ASSIGNORS:SAWA, YOSHIKI;MIYAGAWEA, SHIGERU;SAKAI, YOSHIKI;AND OTHERS;SIGNING DATES FROM 20200217 TO 20200220;REEL/FRAME:055578/0840 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CUORIPS INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARDIO INCORPORATED;REEL/FRAME:060566/0063 Effective date: 20220606 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |